METHOCARBAMOL Drug Patent Profile

When do Methocarbamol patents expire, and what generic alternatives are available?

Methocarbamol is a drug marketed by Dr Reddys, Marsam Pharms Llc, Am Regent, Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Gland, Monterey Pharms Llc, Navinta Llc, Pharmobedient, Sagent Pharms Inc, Slate Run Pharma, Somerset Theraps Llc, Able, Aiping Pharm Inc, Am Therap, Ani Pharms, Ascot, Aurobindo Pharma Ltd, Bostal, Chartwell Molecular, Clonmel Hlthcare, Granules, Heather, Hetero Labs Ltd Iii, Hikma Intl Pharms, Impax Labs, Inwood Labs, Ivax Sub Teva Pharms, Kv Pharm, Mikart, Mylan, Nylos, Oxford Pharms, Pioneer Pharms, Pointview Hldings, Prinston Inc, Puracap Pharm, Purepac Pharm, Regcon Holdings, Roxane, Sandoz, Solvay, Sun Pharm Industries, Superpharm, Tablicaps, Upsher Smith, Watson Labs, Mcneil, Par Pharm, and Stevens J. and is included in seventy-four NDAs.

The generic ingredient in METHOCARBAMOL is aspirin; methocarbamol. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; methocarbamol profile page.

Summary for METHOCARBAMOL

US Patents:	0
Applicants:	51
NDAs:	74
Finished Product Suppliers / Packagers:	64
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
Patent Applications:	3,847
Drug Prices:	Drug price information for METHOCARBAMOL
Drug Sales Revenues:	Drug sales revenues for METHOCARBAMOL
DailyMed Link:	METHOCARBAMOL at DailyMed

See drug prices for METHOCARBAMOL

See drug sales revenues for METHOCARBAMOL

Recent Clinical Trials for METHOCARBAMOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Friends Research Institute, Inc.	PHASE4
MATClinics	PHASE4
Arthritis Innovation Corporation	Phase 3

See all METHOCARBAMOL clinical trials

Pharmacology for METHOCARBAMOL

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

Medical Subject Heading (MeSH) Categories for METHOCARBAMOL

Muscle Relaxants, Central

Anatomical Therapeutic Chemical (ATC) Classes for METHOCARBAMOL

M03BA	Carbamic acid esters
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

US Patents and Regulatory Information for METHOCARBAMOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solvay	METHOCARBAMOL	methocarbamol	TABLET;ORAL	084448-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Impax Labs	METHOCARBAMOL	methocarbamol	TABLET;ORAL	084927-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Clonmel Hlthcare	METHOCARBAMOL	methocarbamol	TABLET;ORAL	085963-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mcneil	METHOCARBAMOL AND ASPIRIN	aspirin; methocarbamol	TABLET;ORAL	089193-001	Feb 12, 1986		DISCN	No	No
Mylan	METHOCARBAMOL	methocarbamol	TABLET;ORAL	084259-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Prinston Inc	METHOCARBAMOL	methocarbamol	TABLET;ORAL	086988-002	Approved Prior to Jan 1, 1982	AA	RX	No	No

METHOCARBAMOL Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Methocarbamol?

Methocarbamol is a centrally acting muscle relaxant used to treat acute musculoskeletal conditions. The drug's market is influenced by clinical demand, competitive landscape, regulatory status, and healthcare trends.

Market Demand Drivers

• Incidence of Musculoskeletal Disorders: The global prevalence of conditions such as back pain and muscle sprains fuels demand (WHO reports a rise in musculoskeletal pain, notably in aging populations).
• Shift Toward Conservative Treatment: Preference for non-invasive therapies increases reliance on muscle relaxants, including methocarbamol.
• Rising Healthcare Spending: Growth in outpatient care and pain management therapies expands the market for muscle relaxants.
• Generic Availability: Patent expirations have allowed multiple manufacturers to produce methocarbamol, increasing supply and reducing prices.

Competitive Landscape

• Key Players: Several pharmaceutical companies produce methocarbamol, including Mylan, Teva, and Sun Pharmaceutical Industries.
• Alternatives Use: Other muscle relaxants such as carisoprodol, cyclobenzaprine, and baclofen compete in the same therapeutic category.
• Formulation Trends: Development of combination therapies (e.g., methocarbamol with acetaminophen) influences market share.

Regulatory and Policy Factors

• FDA Status: Methocarbamol is approved for medical use in the U.S. and many other countries, with a well-established safety profile.
• Prescription Trends: Increased scrutiny on opioid-sparing pain treatments elevates demand for non-opioid muscle relaxants.
• Pricing and Reimbursement: Payer policies favor lower-cost generics, supporting steady demand.

Challenges and Limitations

• Side Effects and Usage Restrictions: Dizziness, sedation, and limited evidence on long-term efficacy restrict broader use.
• Patent and IP Barriers: As a generic drug, methocarbamol faces minimal patent restrictions but competes on price.

What Is the Financial Trajectory of Methocarbamol?

Forecasting the financial trajectory involves analyzing sales volume, pricing, and market penetration dynamics.

Historical Sales Data

• The global muscle relaxant drugs market was valued at approximately USD 2.3 billion in 2021.
• Methocarbamol's share is part of this broad category, with generic formulations accounting for the majority of sales.

Revenue and Market Share Estimates

Metric	2021	2022	2023 (Projection)	Notes
Global muscle relaxant market	USD 2.3B	USD 2.4B	USD 2.6B	Slight growth due to increased musculoskeletal issues
Methocarbamol market share	~15%	~16%	~17%	Driven by generic sales, stable demand

Price Trends

• Average wholesale prices for methocarbamol have declined marginally over the past three years due to increased competition.
• The price per unit (per 100mL injection or per 500mg tablet) averages USD 0.10–0.15.

Profitability Outlook

• Gross margins for generic drugs like methocarbamol typically range from 40% to 60%, influenced largely by manufacturing costs and pricing strategies.
• Revenue growth primarily depends on market penetration in primary care and pain clinics.

Future Market Drivers

• Aging populations in North America and Europe increase potential demand.
• Expansion into emerging markets with growing healthcare infrastructure could provide additional revenue streams.
• Adoption of combination therapies and injectable formulations may open new segments.

Risks

• Patent erosion for proprietary formulations offers limited upside.
• Regulatory changes or adverse safety reports could depress sales.
• Pricing pressures and tendering in institutional markets impact profitability.

Key Takeaways

• The methocarbamol market benefits from steady demand for non-opioid muscle relaxants.
• Manufacturers compete mainly on price, with generic formulations dominating sales.
• Market growth remains modest, around 5-7% annually, aligned with general musculoskeletal disorder prevalence.
• Regulatory stability and healthcare trends favor existing formulations; innovation opportunities are limited.
• Revenue growth hinges on market access in emerging economies and the development of new formulations.

FAQs

1. How does methocarbamol compare to other muscle relaxants?
Methocarbamol has a favorable safety profile but is often less potent than alternatives like cyclobenzaprine. Costs and side-effect profiles influence prescribing decisions.

2. What factors could impact future sales of methocarbamol?
Changes in clinical guidelines favoring newer therapies, safety concerns, or shifts to alternative treatments like physical therapy could impact sales.

3. Are there any authorized patents or exclusivities for methocarbamol?
As a generic drug, patent protections are minimal. Some formulations may have exclusivity periods, but overall, the market is highly commoditized.

4. Which regions represent the best growth opportunities?
Emerging markets in Asia-Pacific and Latin America, where healthcare infrastructure is expanding, offer potential for increased sales.

5. Is there ongoing innovation for methocarbamol?
Research focuses on combination therapies and novel delivery mechanisms, but no significant new formulations have disrupted the market recently.

---

References

[1] World Health Organization. Musculoskeletal Conditions. 2021.
[2] Global Market Insights. Muscle Relaxants Market Report. 2022.
[3] U.S. Food and Drug Administration. Drug Approvals and Labeling. 2023.